The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).
- Conditions
- TonsillectomyPostoperative ComplicationsAdenoidectomySleep Apnea, Obstructive
- Interventions
- Drug: PlaceboDrug: Caffeine
- Registration Number
- NCT00273754
- Lead Sponsor
- The University of Texas Health Science Center, Houston
- Brief Summary
This is a research study using caffeine in children who have an obstructive sleep apnea (OSA). OSA means children who stop breathing during their sleep due to obstruction in their airway. The purpose of this study is to determine whether caffeine when given in the vein, will wake children up faster and decrease post-anesthesia airway obstruction, as well as the safety and if the drug agrees with the child compared to a placebo (an inactive or dummy agent).
- Detailed Description
Patients with OSA are reported to have a higher rate of severe respiratory complications associated with upper airway obstruction during anesthesia and sedation or immediately after anesthesia. Children with OSA (especially those under three years of age, those with severe OSA, cerebral palsy or craniofacial anomalies) are at increased risks for post-operative complications, and require careful monitoring post-operatively.
Although the etiology of obstructive sleep apnea is mainly obstruction due to anatomical and neuromuscular abnormalities, we believe that a central element may contribute to OSA.
The aim of this study is to evaluate whether administration of caffeine to children with OSA, scheduled for elective T \& A under general anesthesia contributes to a faster recovery, less post-operative complications, and a shorter stay in the PACU, DSU and the hospital.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 74
- Children between 2.5-18 years old
- Diagnosed with obstructive sleep apnea
- Undergoing elective tonsillectomy and adenoidectomy
- Age below 2.5 or above 18 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Saline Caffeine Caffeine Caffeine benzoate
- Primary Outcome Measures
Name Time Method Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. The number of children having adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation \<95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the Operating Room and in the PACU was recorded.
- Secondary Outcome Measures
Name Time Method Extubation Time. Duration from anesthesia end until extubation time. Time from end of anesthesia until extubation.
Occurence of Post Extubatory Respiratory Adverse Events. Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. The overall occurance of adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation \<95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the OR and in the PACU was noted.
Awakening Time Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score. A child with a Steward Recovery Scale score of 6 is defined as awake, coughing/crying, and has purposeful movements.
Post Anesthesia Care Unit (PACU) Duration Time spent in PACU following surgical procedure prior to discharge home or hospital admission. Hospital Discharge Time Total time from end anesthesia to discharge home Children were discharged from the hospital when they reached the hospital discharge criteria: they were awake, had stable vital signs, were breathing adequately, had O2 saturation \>95% while breathing room air, were able to swallow fluids, had no or minimal pain, and were able to ambulate without excessive nausea, vomiting, or dizziness.
Trial Locations
- Locations (1)
University of Texas, Health Science Center at Houston, Children's Memorial Hermann Hospital
🇺🇸Houston, Texas, United States